Table 3.

Univariate and multivariable Cox regression analysis of progression predictors on AS using full and modified criteria

	Univariate		Multivariate
	HR (95% CI)	p Value	HR (95% CI)	p Value
Full criteria
Biopsy 2 PSA	1.31 (1.17–1.47)	<0.0005	1.29 (1.14–1.46)	<0.0005
Ca evidence at biopsy 2 (yes vs no)	2.17 (1.30–3.63)	0.003	1.75 (1.01–3.04)	0.047
PSA density	1.09 (1.04–1.15)	0.0005	1.06 (0.99–1.12)	0.075
3 Pos cores at biopsy 2 (yes vs no)	3.71 (1.57–8.78)	0.003	2.42 (0.97–6.05)	0.058
10 or More cores at biopsy 1 (yes vs no)	0.85 (0.49–1.45)	0.5	0.81 (0.47–1.39)	0.4
Age at biopsy 2	1.01 (0.98–1.05)	0.5	—
Prostate vol	1.01 (1.00–1.01)	0.1	—
Biopsy 2 within 6 mos of biopsy 1 (yes vs no)	0.94 (0.56–1.58)	0.8	—
Biopsy 2 lat (bilat vs unilat)	1.19 (0.47–3.01)	0.7	—
Biopsy 2 clinical stage:
T1a/b/c	Referent		—
T2a	1.22 (0.60–2.49)	0.6	—
Modified criteria
Biopsy 2 PSA	1.14 (0.98–1.33)	0.09	1.13 (0.95–1.35)	0.18
Ca evidence at biopsy 2 (yes vs no)	3.22 (1.55–6.68)	0.002	3.16 (1.41–7.09)	0.005
PSA density	1.09 (1.02–1.18)	0.018	1.06 (0.97–1.16)	0.19
3 Pos cores at biopsy 2 (yes vs no)	4.00 (1.19–13.40)	0.025	2.40 (0.66–8.77)	0.18
10 or More cores at biopsy 1 (yes vs no)	0.78 (0.37–1.64)	0.5	0.69 (0.32–1.46)	0.3
Age at biopsy 2	1.05 (0.99–1.10)	0.092	—
Prostate vol	1.00 (0.99–1.01)	0.9	—
Biopsy 2 within 6 mos of biopsy 1 (yes vs no)	1.21 (0.59–2.50)	0.6	—
Biopsy 2 lat (bilat vs unilat)	1.18 (0.28–4.98)	0.8	—
Biopsy 2 clinical stage:
T1a/b/c	Referent		—
T2a	1.51 (0.61–3.69)	0.4	—